[1] Freedman DM, Looker AC, Abnet CC,et al. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES Ⅲ Study (1988~2006)[J].Cancer Res,2010, 70(21) : 8587-8597. [2] Manson JE, Mayne ST, Clinton SK.Vitamin D and prevention of cancer-ready for prime time[J].N Engl J Med,2011,364(15):1385-1387. [3] Drake MT, Maurer MJ, Link BK,et al.Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma[J].J Clin Oncol,2010, 28(27):4191-4198. [4] Thomas X, Chelghoum Y, Fanari N,et al. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies[J].Hematology,2011, 16(5): 278-283. [5] 张之南. 血液病诊断及疗效标准[M]. 第2版. 北京:科学出版社,1998:185. [6] 丁江华. 三氧化二砷治疗急性早幼粒细胞白血病的新认识 [J].安徽医药,2006, 10(2): 146-147. [7] Wang X, Studzinski GP. Oncoprotein cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells.[J].J Cell Physiol,2011, 226(5): 1232-1240. [8] Winkel ML, Beek RD, Muinck SM,et al. Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia [J].Haematologica,2010, 95(5): 752-759. [9] 郑敏,何云燕,罗建明. 1, 25-二羟基维生素D3对白血病 6T-CEM细胞株作用的体外研究[J].广西医学,2013,35(6): 730- 731. [10] Niitsu N, Umeda M, Honma Y. Mycloid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs[J].Leuk Res,2000, 24(1): 1-9.
2016, Vol. 33 
